Wiener Medizinische Wochenschrift

, Volume 160, Issue 15–16, pp 391–398

Adipozytokine bei Rheumatoider Arthritis und Adipositas

Themenschwerpunkt

Zusammenfassung

Bei adipösen RA-Patienten stehen Entzündungsmechanismen und kardiovaskuläre Begleiterkrankungen möglicherweise in Beziehung zur geänderten Expression von Adipozytokinen. 112 Patienten (23,2 % Männer; 76,8 % Frauen) mit RA wurden hinsichtlich verschiedener Adipozytokine und Entzündungsparameter untersucht: Leptin, Adiponektin, Visfatin, sCD40 L, CRP und BSG. Der durchschnittliche BMI lag bei 27,6 (±5,6). Während Leptin und Visfatin mit dem BMI positiv korrelierten, zeigte sich zwischen BMI und Adiponektin eine inverse Korrelation. Zwischen normalgewichtigen und adipösen RA Patienten bestand bezüglich Leptin und Adiponektin ein signifikanter Unterschied. Visfatin korrelierte positiv mit dem Entzündungsparameter CRP; sCD40 Ligand, ein Marker für gesteigerte T-Zell-Aktivität, korrelierte mit CRP und BSG. Patienten mit niedrigem Adiponektinspiegel (<10 µg/ml) hatten häufiger eine kardiovaskuläre Erkrankung (28,6 %) als Patienten mit hohem Adiponektin (14,3 %). Die Erhöhung von proinflammatorischem Leptin bzw. Verminderung von entzündungshemmendem Adiponektin bei adipösen RA-Patienten ist in Verbindung mit der Aktivität der RA und einem erhöhten kardiovaskulären Risiko zu sehen.

Schlüsselwörter

Rheumatoide Arthritis Adipositas Kardiovaskuläre Erkrankung Adiponektin Leptin Visfatin 

Adipocytokines in rheumatoid arthritis and obesity

Summary

In obese rheumatoid arthritis (RA) patients inflammatory mechanisms and cardiovascular secondary disorders are possibly related to changed expression of adipocytokines. Various adipocytokines and inflammatory parameters were examined in 112 patients (23.2% men; 76.8% women) suffering from RA: leptin, adiponectin, visfatin, sCD40 L, CRP, and ESR. Average BMI was 27.6 (±5.6). Leptin and BMI as well as visfatin and BMI correlated positively, BMI and adiponectin, however, showed a negative correlation. Significant differences between normal-weight and obese RA patients were found in both leptin and adiponectin measurements. Visfatin showed a positive correlation with CRP; sCD40 ligand which is a marker for increased T-cell activity correlated with CRP and ESR. Patients with low adiponectin levels (<10 µg/ml) more often suffered from cardiovascular diseases (28.6%) than those with enhanced adiponectin (14.3%). Increased pro-inflammatory leptin and decreased anti-inflammatory adiponectin in obese RA patients can be associated with RA activity and enhanced cardiovascular risk.

Keywords

Rheumatoid arthritis Obesity Cardiovascular diseases Adiponectin Leptin Visfatin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Neumann E, Knedla A, Meier F, et al. Adipozytokine als treibende Faktoren bei rheumatoider Arthritis. Z Rheumatol, 66: 139–141, 2007CrossRefPubMedGoogle Scholar
  2. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 100: 2473–2476, 1999PubMedGoogle Scholar
  3. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 96: 1723–1732, 2000PubMedGoogle Scholar
  4. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunmodulating properties. J Immunol, 178: 1748–1758, 2007PubMedGoogle Scholar
  5. Otero M, Lago R, Gomez R, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis, 65: 1198–1201, 2006CrossRefPubMedGoogle Scholar
  6. Niksic F, Burmucic K, Kullich W, et al. Kardiovaskuläre Manifestationen bei entzündlich rheumatischen Erkrankungen. Wien Med Wochenschr, 152: 220–222, 2002CrossRefPubMedGoogle Scholar
  7. World Medical Association General Assembly, Tokio. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Int Bioethique, 15: 124–129, 2004CrossRefGoogle Scholar
  8. WHO Consultation on Obesity. Obesity. Preventing and managing the global epidemic. Genf: Weltgesundheitsorganisation; 1998Google Scholar
  9. Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, et al. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr (Rio J), 83: 192–103, 2007CrossRefGoogle Scholar
  10. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev, 6(10 Pt 2): S1–S14, 2002; discussion S68–S84, 85–87CrossRefGoogle Scholar
  11. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med, 334: 292–295, 1996CrossRefPubMedGoogle Scholar
  12. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. Z J Immunol, 173: 3137–3142, 2005Google Scholar
  13. Park MC, Lee SW, Choi ST, et al. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol, 36: 101–106, 2007CrossRefPubMedGoogle Scholar
  14. Bokarewa M, Bokarewa D, Hultgren O, et al. Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis, 62: 952–956, 2003CrossRefPubMedGoogle Scholar
  15. Gunaydin R, Kaya T, Atay A, et al. Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J, 99: 1078–1083, 2006PubMedGoogle Scholar
  16. Wislowska M, Rok M, Jaszczyk B, et al. Serum leptin in rheumatoid arthritis. Rheumatol Int, 27: 947–954, 2007CrossRefPubMedGoogle Scholar
  17. Yamagishi SI, Edelstein D, Du XL, et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem, 276: 25096–25100, 2001CrossRefPubMedGoogle Scholar
  18. Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation, 106: 1904–1905, 2002CrossRefPubMedGoogle Scholar
  19. Konstantinides S, Schafer K, Koschnick S, et al. Leptindependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest, 108: 1533–1540, 2001PubMedGoogle Scholar
  20. Radovits BJ, Popa-Diaconu DA, Popa C, et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis, 68: 1271–1276, 2009CrossRefPubMedGoogle Scholar
  21. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas V, et al. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis, 68: 242–245, 2009CrossRefPubMedGoogle Scholar
  22. Laurberg TB, Frystyk J, Ellingsen T, et al. Plasma Adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naïve compared with patients with osteoarthritis and controls. J Rheumatol, 36: 1885–1891, 2009CrossRefPubMedGoogle Scholar
  23. Saltevo J, Kautiainen H, Vanhala M. Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes. Gend Med, 6: 463–470, 2009CrossRefPubMedGoogle Scholar
  24. He H, Ni Y, Chen J, et al. Sex difference in cardiometabolic risk profile and adiponectin expression in subjects with visceral fat obesity. Transl Res, 155: 71–77, 2010CrossRefPubMedGoogle Scholar
  25. Lau CW, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol, 288: H2031–H2041, 2005CrossRefPubMedGoogle Scholar
  26. Guzik TJ, Mangalat D, Korbut R. Adipocytokines – Novel link between inflammation and vascular function? J Physiol Pharmacol, 57: 505–528, 2006PubMedGoogle Scholar
  27. Otero M, Lago R, Gomez R, et al. Towards a pro-inflammatory and immunmodulatory emerging role of leptin. Rheumatology (Oxf), 45: 944–950, 2006CrossRefGoogle Scholar
  28. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism, 56: 1131–1134, 2007CrossRefPubMedGoogle Scholar
  29. Körner A, Garten A, Blüher M, et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab, 92: 4783–4791, 2007CrossRefPubMedGoogle Scholar
  30. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation, 107: 671–674, 2003CrossRefPubMedGoogle Scholar
  31. Lemieux I, Pascot A, Prud’homme D, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol, 21: 961–967, 2001PubMedGoogle Scholar
  32. Oki K, Yamane K, Kamei N, et al. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf), 67: 796–800, 2007CrossRefGoogle Scholar
  33. Berner B, Wolf G, Hummel KM, et al. Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis, 59: 190–195, 2000CrossRefPubMedGoogle Scholar
  34. Toubi E, Shoenfeld Y. The role of CD40–CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity, 37: 457–464, 2004CrossRefPubMedGoogle Scholar
  35. Tamura N, Kobayashi S, Kato K, et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol, 28: 2583–2590, 2001PubMedGoogle Scholar
  36. Corson MA. Emerging inflammatory markers for assessing coronary heart disease risk. Curr Cardiol Rep, 11: 452–459, 2009CrossRefPubMedGoogle Scholar
  37. Contin C, Pitard V, Itai T, et al. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J Biol Chem, 278: 32801–32809, 2003CrossRefPubMedGoogle Scholar
  38. Sanchez C, Mateus MM, Defresne M-P, et al. Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1 β and nonsteroidal anti-inflammatory drugs. J Rheumatol, 29: 772–782, 2002PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Ludwig Boltzmann Cluster für Rheumatologie, Balneologie und RehabilitationLudwig Boltzmann Institut für Rehabilitation interner ErkrankungenSaalfeldenAustria

Personalised recommendations